Literature DB >> 7545084

Monoclonal antibody BW835 defines a site-specific Thomsen-Friedenreich disaccharide linked to threonine within the VTSA motif of MUC1 tandem repeats.

F G Hanisch1, T Stadie, K Bosslet.   

Abstract

mAb BW835 (IgG1) has been generated to breast cancer cell lines by alternating injections of MCF-7 or SW-613 cells and has been demonstrated to be of value in the serodiagnosis of mammary carcinoma. BW835 defines a carbohydrate epitope on integrated or secreted MUC1 glycoforms from carcinoma cells and human milk. To identify BW835-reactive glycopeptides on MUC1, proteolytic fragments of the mucin obtained by digestion with the Gly-C-specific endopeptidase IV from papaya corresponding to low molecular mass fragments (< 10 kilodaltons) of the tandem repeat domain were screened. A glycosylated fragment (glycopeptide 17) containing the mAb HMFG-2-defined epitope was highly reactive to BW835 antibody, while nonglycosylated tandem repeat peptide TAP25 or its in vitro-glycosylated N-acetylgalactosamine (GalNAc) derivatives were unreactive. Glycopeptide 17 bound to peanut agglutinin and to a Thomsen-Friedenreich antigen (TF alpha)-specific mAb (A78-G/A7). Binding of BW835 to glycopeptide 17 or to MUC1 was competitively inhibited by peanut agglutinin and by the synthetic glycopeptides TF alpha Ser or TF alpha Thr but not by their beta-anomers. Evidence for site specificity of binding by BW835 to glycopeptide 17 was revealed by demonstrating nonreactivity of the antibody to other TF alpha-expressing glycoproteins with peptide moieties lacking MUC1-specific motifs at putative glycosylation sites. The epitope of BW835 was localized to threonine within the VTSA-peptide motif by site-specific enzymatic beta-galactosylation of the synthetic tandem repeat peptide TAP25-GalNAc1 TAPPAHGVT(-O-alpha GalNAc)SAPDTRPAPGSTAPPA. This is the first report on a TF alpha-specific mAb that shows a strict peptide sequence dependency of binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545084

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  NEU1 sialidase expressed in human airway epithelia regulates epidermal growth factor receptor (EGFR) and MUC1 protein signaling.

Authors:  Erik P Lillehoj; Sang Won Hyun; Chiguang Feng; Lei Zhang; Anguo Liu; Wei Guang; Chinh Nguyen; Irina G Luzina; Sergei P Atamas; Antonino Passaniti; William S Twaddell; Adam C Puché; Lai-Xi Wang; Alan S Cross; Simeon E Goldblum
Journal:  J Biol Chem       Date:  2012-01-13       Impact factor: 5.157

2.  Development and characterization of an antibody directed to an alpha-N-acetyl-D-galactosamine glycosylated MUC2 peptide.

Authors:  C A Reis; T Sørensen; U Mandel; L David; E Mirgorodskaya; P Roepstorff; J Kihlberg; J E Hansen; H Clausen
Journal:  Glycoconj J       Date:  1998-01       Impact factor: 2.916

3.  Mucin-Type O-GalNAc Glycosylation in Health and Disease.

Authors:  Ieva Bagdonaite; Emil M H Pallesen; Mathias I Nielsen; Eric P Bennett; Hans H Wandall
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 4.  The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression.

Authors:  Lu-Gang Yu
Journal:  Glycoconj J       Date:  2007-04-25       Impact factor: 2.916

5.  Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.

Authors:  Loukia G Karacosta; John C Fisk; Joseph Jessee; Swetha Tati; Bradley Turner; Diala Ghazal; Rachel Ludwig; Holly Johnson; Julia Adams; Munawwar Sajjad; Steven Koury; Rene Roy; James R Olson; Kate Rittenhouse-Olson
Journal:  Transl Oncol       Date:  2018-02-22       Impact factor: 4.243

Review 6.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.